Download
s00345-020-03497-1.pdf 847,24KB
WeightNameValue
1000 Titel
  • Immunotherapy in prostate cancer: new horizon of hurdles and hopes
1000 Autor/in
  1. Tsaur, Igor |
  2. Brandt, Maximilian P. |
  3. Juengel, Eva |
  4. Manceau, Cécile |
  5. Ploussard, Guillaume |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-10-26
1000 Erschienen in
1000 Quellenangabe
  • 39(5):1387-1403
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00345-020-03497-1 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514362/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!Prostate cancer (PCa) is the most common malignancy in men and the cause for the second most common cancer-related death in the western world. Despite ongoing development of novel approaches such as second generation androgen receptor targeted therapies, metastatic disease is still fatal. In PCa, immunotherapy (IT) has not reached a therapeutic breakthrough as compared to several other solid tumors yet. We aimed at highlighting the underlying cellular mechanisms crucial for IT in PCa and giving an update of the most essential past and ongoing clinical trials in the field.!##!Methods!#!We searched for relevant publications on molecular and cellular mechanisms involved in the PCa tumor microenvironment and response to IT as well as completed and ongoing IT studies and screened appropriate abstracts of international congresses.!##!Results!#!Tumor progression and patient outcomes depend on complex cellular and molecular interactions of the tumor with the host immune system, driven rather dormant in case of PCa. Sipuleucel-T and pembrolizumab are the only registered immune-oncology drugs to treat this malignancy. A plethora of studies assess combination of immunotherapy with other agents or treatment modalities like radiation therapy which might increase its antineoplastic activity. No robust and clinically relevant prognostic or predictive biomarkers have been established yet.!##!Conclusion!#!Despite immunosuppressive functional status of PCa microenvironment, current evidence, based on cellular and molecular conditions, encourages further research in this field.
1000 Sacherschließung
lokal Topic Paper
lokal Immune checkpoints
lokal Male [MeSH]
lokal PD-L1
lokal Humans [MeSH]
lokal Immunotherapy
lokal Prostatic Neoplasms/therapy [MeSH]
lokal Vaccine
lokal Immunotherapy [MeSH]
lokal PD-1
lokal Prostate cancer
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0001-5107-3523|https://frl.publisso.de/adhoc/uri/QnJhbmR0LCBNYXhpbWlsaWFuIFAu|https://frl.publisso.de/adhoc/uri/SnVlbmdlbCwgRXZh|https://frl.publisso.de/adhoc/uri/TWFuY2VhdSwgQ8OpY2lsZQ==|https://frl.publisso.de/adhoc/uri/UGxvdXNzYXJkLCBHdWlsbGF1bWU=
1000 Hinweis
  • DeepGreen-ID: d6479dcb90c74ac480b2a38a9d220f61 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
  1. Immunotherapy in prostate cancer: new horizon of hurdles and hopes
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6466876.rdf
1000 Erstellt am 2023-11-17T04:22:20.202+0100
1000 Erstellt von 322
1000 beschreibt frl:6466876
1000 Zuletzt bearbeitet Fri Dec 01 05:00:20 CET 2023
1000 Objekt bearb. Fri Dec 01 05:00:20 CET 2023
1000 Vgl. frl:6466876
1000 Oai Id
  1. oai:frl.publisso.de:frl:6466876 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source